Funding Announcements

Filter

Filter & sort

Keyword

Tag

Round

Sort by

Clear

The latest funding rounds from the UK tech ecosystem. Updated 31 July 2026.

Seed
£1.6M

The laboratory simulator firm raised the funds from new investor Foresight Group alongside Mercia and Finance Yorkshire.

"Laboratory equipment is challenging to operate and technical problems are commonplace. Each service call-out typically costs manufacturers $2,500 and a breakdown can seriously disrupt health services by delaying critical test results. Envoke is tackling these problems. Customer feedback shows our system helps laboratories to reduce downtime and provide more consistent operator training, while enabling manufacturers to cut service costs and boost revenue."
— Stuart Warrington, CEO
Seed
£4.0M

The seed round was led by Seraphim Space with backing from prominent technology founders and investors.

"Persistent maritime coverage has been too expensive for too long. That has limited what governments and operators can actually see, protect and respond to at sea. We built Online Oceans to change that. This funding allows us to scale production and support customers who need a far more practical way to monitor critical waters, protect infrastructure and maintain awareness over long periods."
— George Morton, Founder and CEO
Seed
£3.9M

The seed round was led by Notion Capital with backing from a16z Speedrun and Concept Ventures 2100.

"Traditional recruitment is often unsuccessful and, so far, AI hasn’t helped much. We’re currently seeing an AI ‘arms race’ to the bottom, with companies being flooded by AI-generated applications, while individuals are often subjected to inhumane – and unethical – screening. Dex offers an alternative. We’re excited about this seed funding, which will drive our ambition of redefining how talent and opportunity connect."
— Paddy Lambros, Co-Founder and CEO
Seed
£3.7M

The oversubscribed financing round was funded entirely by the company's existing investor base.

"The decision by our existing shareholders to reinvest, and to do so at a level that exceeded our target, speaks directly to their confidence in what PlaqueTec’s data is revealing about cardiovascular disease. We are building something genuinely differentiated: a high-resolution, intracoronary data asset that is poised to underpin the next generation of cardiovascular therapeutics. This round validates that strategy and gives us the runway to prove it."
— Martin Stapleton, Chairman